The author has studied nerve growth factor (NGF) and its family of neurotrophic factors (neurotrophins) for over 40 years. During theˆrst 20 years, my laboratory established a highly sensitive enzyme immunoassay for NGF and analyzed the regulatory mechanism of NGF synthesis in cultured primary cells. Fibroblast cells cultured from peripheral organs such as the heart and astrocytes from the brain produced a substantial amount of NGF in a growth-dependent manner. Furthermore, synthesis of NGF in these cells could be upregulated by catechol compounds including catecholamines. This observation might explain a physiological relation between the level of NGF mRNA and the density of innervation in the peripheral sympathetic nervous systems. Over the subsequent 20 years, my laboratory investigated the physiological functions of neurotrophic factors, including neurotrophins, during development or post-injury and found that brain-derived neurotrophic factor (BDNF) plays a role in the formation of the laminar structure of the cerebral cortex. In addition, my laboratory discovered that endogenous glial cell line-derived neurotrophic factor (GDNF) contributes to the amelioration of motor activity after spinal cord injury. Therefore we aimed to develop low-molecular weight compounds that generate neurotrophic factor-like intracellular signals to protect or ameliorate neurological/psychiatric diseases. 2-Decenoic acid derivatives and other similar molecules could protect or ameliorate in animal models of mood disorders such as depression and enhance recovery from spinal cord injury-induced motor paralysis. Compounds that can generate neurotrophin-like signals in neurons are expected to be developed as therapeutic drugs for certain neurological or psychiatric disorders.
NGF is physiologically synthesized and secreted in an activity-dependent manner by various neurons in a normal adult brain. In this way, NGF acts locally as a neurotrophic factor. However, the degree of injury or type of brain insult may change the manner and/or the cell type responsible for NGF synthesis. During diabetic coma, ischemia-reperfusion, or excitotoxicity, particular neurons can be overexcited and lead to increased NGF production (◯ ). After massive neuronal cell death, reactive astrocytes expressing glialˆbrillary acidic protein (◯ ) are induced and begin to produce NGF. After in‰ammation, microglia (◯ ) and macrophages (◯ ) are activated and start to synthesize NGF. In this case, NGF acts both as a cytokine and as a neurotrophic factor in particular neurons. Stroke, the most serious brain disease, causes invasion and activation of T cells sensitized to the nerve tissues (◯ ), and such activated T cells participate in the production of NGF. Mice were given CORT (20 mg/kg) by the subcutaneous route and/or each drug orally once a day for 21 days (n＝6/group). I: The time spent immobilized was measured by performing the tail suspension test. II: The time spent in open arms was evaluated. III: The hippocampus was dissected out 1 day after theˆnal CORT administration and used for western immunoblot analysis. The ratio of intensity of the pERK1/2 band to that of the total ERK1/2 band was calculated, and the values were expressed as a fold-increase over the value of the non-CORT-treated and vehicle-administered group, taken as``1.'' The signiˆcance of the diŠerence between the values of the CORT-treated groups and those of the vehicle-treated groups was determined by one-way ANOVA with Tukey's post hoc test ( p＜0.05,   p＜0.01 (n＝6/group)). Among the CORT-treated groups, signiˆcant diŠerences from the vehicle-treated group were also determined by one-way ANOVA with Tukey's post hoc test ( # p＜0.05(n＝6/group)). Injury-induced neurotrophic factors (NTs) are very small around the site of injury (◯ ) and are thus not transported to the neuronal cell body (◯ ). Therefore, events leading to nerve regeneration do not take place in the nucleus of neurons that send axons to the spinal cord. However, DAD is delivered to the nucleus through the blood vessels and acts like NTs. Consequently, the molecules to be used for nerve regeneration are produced in the neuronal cell body and transported to the injury site. 
